XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX (NASDAQ: XRTX) announced results of its annual and special meeting held March 24, 2026.

Rhea-AI Summary

XORTX (NASDAQ: XRTX) announced results of its annual and special meeting held March 24, 2026. Approximately 2,407,148 common shares were represented, about 35% of outstanding shares. All matters presented were approved, including election of five directors, auditor appointment, reapproval of the stock option plan, and approval of a share consolidation.

Detailed voting results are available in the Report of Voting Results filed on the company’s SEDAR+ profile.

Argus Mar 27 session

+9.88% close to close Open Argus

Details

News Market Reaction – XRTX

On Mar 27, the first trading day after this news, XRTX closed 9.88% above the previous close.

Data tracked by StockTitan Argus for the Mar 27 session.

Key Figures

Current price: $0.345 52-week high: $1.41 52-week low: $0.3635 +5 more

Current price

$0.345

Pre‑news close versus shareholder meeting announcement

52-week high

$1.41

Stock trading 75.53% below high before meeting results

52-week low

$0.3635

Price 5.09% below 52-week low level pre‑news

Shares represented

2,407,148 shares

Common shares represented at March 24, 2026 shareholder meeting

Participation rate

35%

Portion of issued and outstanding common shares represented at meeting

Board nominees

5 directors

Number of management nominees elected at the annual and special meeting

Market cap

$2,659,567

Equity value pre‑news based on latest close

Relative volume

1.68x

Today’s volume vs. 20‑day average before meeting results

Historical Context

5 past events · Latest: Mar 24

5 events

1. Mar 24

   Share consolidation approval

   24h Move

   -0.8%

   Shareholders authorized up to 5‑for‑1 share consolidation to support Nasdaq listing.

2. Mar 18

   Director nominees, financing

   24h Move

   +6.5%

   Three substitute director nominees proposed as a condition of significant financing talks.

3. Mar 05

   Meeting materials mailed

   24h Move

   +7.8%

   Filed and mailed meeting documents outlining votes on directors, auditor and consolidation.

4. Feb 04

   Acquisition timeline update

   24h Move

   -17.7%

   Extended deadline to close Vectus renal anti‑fibrotic program acquisition and granted options.

5. Dec 31

   Research & corporate update

   24h Move

   +1.4%

   Highlighted gout genetics research, board changes and completion of a US$1.1M financing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

stock option plan, share consolidation, board of directors, auditors, +1 more

5 terms

stock option plan financial

"re-approval of the stock option plan and approval of the share consolidation."

A stock option plan is a company program that gives employees the right to buy company shares at a preset price after a certain time, like a coupon allowing purchase later at a fixed rate. It matters to investors because these options can increase the number of shares outstanding — reducing each existing share’s ownership slice and potentially changing per-share results — while also aligning employee incentives with boosting the company’s value.

share consolidation financial

"re-approval of the stock option plan and approval of the share consolidation."

Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

board of directors financial

"to the board of directors of the Company, the appointment of Davidson"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

auditors financial

"the appointment of Davidson & Company LLP as auditors of the Company"

Auditors are independent professionals who examine a company’s financial records, internal controls and reporting to verify accuracy and uncover errors or fraud. For investors they act like a building inspector for a company’s finances: a clean audit boosts confidence in the numbers used to value the business, while audit issues or qualifications can signal higher risk and affect stock price and access to capital.

SEDAR+ regulatory

"Report of Voting Results filed on the Company’s SEDAR+ profile at www.sedarplus.ca."

SEDAR+ is Canada’s centralized online system where publicly traded companies submit required regulatory documents such as financial reports, prospectuses and disclosure statements. It gives investors a single, searchable place — like a public library or online filing cabinet — to check a company’s official records for transparency, compare performance, and verify material information before making investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026.

A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all five management nominees (Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George Scorsis) to the board of directors of the Company, the appointment of Davidson & Company LLP as auditors of the Company for the ensuing year and authorization of the directors to fix their remuneration, re-approval of the stock option plan and approval of the share consolidation. Detailed results are available in the Report of Voting Results filed on the Company’s SEDAR+ profile at www.sedarplus.ca.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:

Allen Davidoff, CEO		Nick Rigopulos, Director of Communications
adavidoff@xortx.com		nick@alpineequityadv.com
+1 403 455 7727		+1 617 901 0785

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who was elected to the board at XORTX's March 24, 2026 shareholder meeting (XRTX)?

All five management nominees were elected to the board. According to the company, nominees elected were Anthony Giovinazzo, Allen Davidoff, Mika Grasso, Richard Grieve and George Scorsis, each approved by shareholders at the March 24, 2026 meeting.

What shareholder approvals did XORTX (XRTX) receive at the March 24, 2026 meeting?

Shareholders approved all matters put forward at the meeting. According to the company, approvals included director elections, appointment of Davidson & Company LLP as auditors, reapproval of the stock option plan, and a share consolidation.

How many XORTX (XRTX) shares were represented at the March 24, 2026 meeting and what percent did that represent?

2,407,148 common shares were represented, about 35% of issued and outstanding shares. According to the company, that total represented approximately 35% of the company's common shares at the meeting.

Did XORTX (XRTX) approve a share consolidation at the March 24, 2026 meeting and what does approval mean?

Yes, shareholders approved a share consolidation at the meeting. According to the company, approval authorizes a consolidation of common shares; specific consolidation ratio and timing are provided in filed voting materials or subsequent notices.

Who will serve as XORTX's auditors after the March 24, 2026 shareholder meeting (XRTX)?

Davidson & Company LLP was appointed as auditors for the ensuing year. According to the company, shareholders approved the auditor appointment at the March 24, 2026 annual and special meeting.

Where can investors find the detailed voting results for XORTX's March 24, 2026 meeting (XRTX)?

Detailed voting results are filed on SEDAR+. According to the company, the Report of Voting Results is available on the company’s SEDAR+ profile at www.sedarplus.ca for review.